🔮 OOTWOracle · Live odds · All predictions · Track record

Will MDMA Be FDA-Approved for PTSD? (2026–2027 Odds)

A tracked, falsifiable answer from OOTWOracle · updated September 4, 2026

Not in 2026, and most likely not before 2027. The Oracle currently puts it at 75% that no official rescheduling of psilocybin, MDMA, or ibogaine this year (resolves 2026-12-31). MDMA-assisted therapy for PTSD is the furthest-along psychedelic program, but the FDA has signalled it wants additional confirmatory evidence before approval.

MDMA-assisted therapy for post-traumatic stress disorder is the most advanced psychedelic treatment in the regulatory pipeline. But 'most advanced' is not the same as 'approved': the FDA has pushed for more evidence on durability and trial design, which resets the clock. Here is the honest current read on timing.

Current odds on this question

Oracle odds	Prediction (falsifiable)	Resolves
75%	No official rescheduling of psilocybin, MDMA, or ibogaine this year	2026-12-31
70%	MDMA therapy drug application stays stuck at US regulator	2026-11-15

Every row is a public, dated, falsifiable prediction — scored against a written resolution rule when the date arrives. Methodology & hit-rate: the track record.

Frequently asked

Is MDMA FDA-approved for PTSD?

No. As of September 4, 2026, MDMA has no FDA approval and remains Schedule I. It is in the regulatory pipeline but not cleared.

When could MDMA be approved?

The Oracle's odds favor no approval in 2026; a realistic path runs through a resubmission with new confirmatory data, pushing a decision toward 2027 or later.

Will MDMA be rescheduled?

Rescheduling out of Schedule I generally follows FDA approval of a specific product, so it is not expected ahead of an approval decision.

Why not just approve it now?

The FDA has raised questions about long-term durability and functional-unblinding in the trials; addressing those typically requires additional controlled data.